Antihypertensive Drugs for Liver Disease: Efficacy & Lipid Lowering
Summary of the Article: New Hope for Treating fatty Liver disease
This article discusses a University of Barcelona study published in Pharmacological Research that shows promising results for treating Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as fatty liver disease. Here’s a breakdown of the key points:
* The Problem: MASLD affects roughly one-third of adults globally, leading to severe liver damage and increased risk of cardiovascular disease. Current treatments are limited.
* The Solution (Potential): Researchers found that a combination of two existing drugs – pemafibrate (a lipid-lowering drug) and telmisartan (an antihypertensive) – effectively reduced fat accumulation in the liver in laboratory animal models (rats and zebrafish).
* Why this is meaningful:
* Drug Repurposing: Using drugs already approved for other conditions is a safer, faster, and more cost-effective approach than developing entirely new compounds, which often fail in clinical trials due to safety concerns.
* Targets Early Stages: The study focuses on preventing the disease from progressing to more severe stages, utilizing drugs with established safety profiles.
* Addresses Cardiovascular Risk: MASLD patients frequently enough have cardiovascular risk factors like hyperlipidemia and hypertension, which these drugs also address.
* The Research: The study was conducted by a team led by Marta Alegret at the University of Barcelona, in collaboration with several other research institutions. They used rat and zebrafish models to confirm the drugs’ efficacy and understand how they work.
* Key Finding: The combination of pemafibrate and telmisartan reversed fat accumulation in the liver induced by a high-fat, high-fructose diet.
In essence, this research offers a hopeful avenue for developing more effective and accessible treatments for MASLD by leveraging existing medications.